Subscribe To
AMYT / Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
AMYT News
By Seeking Alpha
April 11, 2023
Amryt Pharma: Final Chance To Pick Up An Attractive CVR
Amryt Pharma is being acquired at $14.50 per share and a contingent value right and is trading at $14.69. The contingent value right consists of 2 mil more_horizontal
By The Motley Fool
January 12, 2023
Why Shares of Amryt Pharma Jumped This Week
A takeover bid by an Italian pharmaceutical and healthcare company boosted Amryt's shares. more_horizontal
By Seeking Alpha
January 12, 2023
Acquisition Of Amryt Pharma: How To Profit From Orphan Drugs Developers
Amryt Pharma plc will be acquired by Chiesi Farmaceutici S.p.A. Amryt Pharma is valued at $1.25 billion plus $225 million upon achievement of certain more_horizontal
By Seeking Alpha
November 5, 2022
Amryt Pharma PLC (AMYT) Q3 2022 Earnings Call Transcript
Amryt Pharma PLC (NASDAQ:AMYT ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Con more_horizontal
By Seeking Alpha
August 6, 2022
Amryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call Transcript
Amryt Pharma plc (NASDAQ:AMYT ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Contr more_horizontal
By Zacks Investment Research
July 14, 2022
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
The FDA bestows an Orphan Drug designation to Amryt's (AMYT) Mycapssa for the treatment of carcinoid syndrome. Stock up in pre-market trading. more_horizontal
By GlobeNewsWire
June 8, 2022
Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022
Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 more_horizontal
By Seeking Alpha
May 8, 2022
Amryt Pharma PLC (AMYT) CEO Joseph Wiley on Q1 2022 Results - Earnings Call Transcript
Amryt Pharma PLC (NASDAQ:AMYT ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Simon Loughrey - Group Financial Controll more_horizontal